Samsung Bioepis continues to prove itself as one of the busiest developers of biosimilars, divulging in quick succession a collection of data and analysis, including for the firm’s SB17 biosimilar Stelara (ustekinumab) candidate for which it recently out-licensed commercialization rights in global markets to Sandoz.
Positive Phase III Ustekinumab Data Puts Samsung Bioepis In The Race
Korean Biosimilars Developer Shares Data For Sandoz-Partnered Stelara Biosimilar
Samsung Bioepis has welcomed positive six-month Phase III data for its SB17 proposed biosimilar to Stelara, the fourth candidate in the company’s immunology pipeline.
More from Biosimilars
• By
Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
• By
In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.
More from Products
• By
Generics Bulletin reviews global regulatory developments across the world.
• By
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
• By
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.